Short Interest in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Increases By 5.1%

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) was the recipient of a large growth in short interest during the month of January. As of January 31st, there was short interest totalling 644,000 shares, a growth of 5.1% from the January 15th total of 612,700 shares. Based on an average daily trading volume, of 33,700 shares, the short-interest ratio is presently 19.1 days. Approximately 10.9% of the company's stock are sold short.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a "buy" rating and issued a $38.00 price objective on shares of Greenwich LifeSciences in a research note on Tuesday, February 11th.

Greenwich LifeSciences Stock Down 0.7 %

Shares of GLSI stock traded down $0.09 during trading hours on Friday, reaching $11.95. The company's stock had a trading volume of 21,061 shares, compared to its average volume of 33,878. Greenwich LifeSciences has a fifty-two week low of $10.52 and a fifty-two week high of $21.44. The company has a market capitalization of $157.08 million, a price-to-earnings ratio of -14.94 and a beta of 1.69. The firm's 50 day simple moving average is $12.49 and its 200-day simple moving average is $13.40.

Insider Buying and Selling at Greenwich LifeSciences

In related news, CEO Snehal Patel acquired 2,500 shares of the business's stock in a transaction on Friday, January 10th. The stock was purchased at an average cost of $12.51 per share, for a total transaction of $31,275.00. Following the completion of the transaction, the chief executive officer now directly owns 5,552,502 shares of the company's stock, valued at approximately $69,461,800.02. The trade was a 0.05 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders have acquired 9,500 shares of company stock worth $115,549. Insiders own 51.67% of the company's stock.

Institutional Trading of Greenwich LifeSciences

A number of institutional investors and hedge funds have recently bought and sold shares of GLSI. Wells Fargo & Company MN increased its stake in shares of Greenwich LifeSciences by 54.8% in the fourth quarter. Wells Fargo & Company MN now owns 2,847 shares of the company's stock valued at $32,000 after buying an additional 1,008 shares during the period. Brown Brothers Harriman & Co. acquired a new stake in Greenwich LifeSciences during the 4th quarter valued at approximately $45,000. JPMorgan Chase & Co. increased its position in Greenwich LifeSciences by 172.0% during the 4th quarter. JPMorgan Chase & Co. now owns 7,061 shares of the company's stock valued at $79,000 after purchasing an additional 4,465 shares during the period. Bank of America Corp DE lifted its position in shares of Greenwich LifeSciences by 22.3% in the 4th quarter. Bank of America Corp DE now owns 7,262 shares of the company's stock worth $82,000 after purchasing an additional 1,322 shares during the period. Finally, Barclays PLC lifted its position in shares of Greenwich LifeSciences by 323.3% in the 3rd quarter. Barclays PLC now owns 8,560 shares of the company's stock worth $123,000 after purchasing an additional 6,538 shares during the period. 4.16% of the stock is currently owned by institutional investors and hedge funds.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.